Alcresta Expands Executive Team to Drive Strategic Growth

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced expansion of the company's leadership team including the promotion of Michael Yeh, M.D. to Chief Medical Officer and the appointment of Ian Vawter as Chief Financial Officer. With these changes, Alcresta is expanding the expertise of the leadership team with two industry executives who will play a vital role in driving multiple strategic initiatives in the years ahead.

"This strategic expansion positions both Michael and Ian to apply their extensive experience to help accelerate our momentum and drive significant progress in our growth trajectory moving forward," said Dan Orlando, Chief Executive Officer. "Michael brings deep clinical and medical affairs expertise that is a key advantage in guiding our medical strategy and in further strengthening the impact we can make on patient lives. On the business strategy and finance side, Ian's experience and leadership will play a vital role in guiding Alcresta's operations as the company advances its commercial success and plans for many exciting new opportunities."